Merck & Co., Inc. (MRK)
NYSE: MRK · Pharmaceutical Preparations · Rahway, NJ · filing with the SEC since 1994
Grade6.7
◀ Past 7.9● Present 7.1▶ Future 5.0
Who owns Merck & Co., Inc.
As filed with the SECHolders of 5% or more
1
Vanguard Capital Management holds 7.53% of Common Stock, as its SCHEDULE 13G filed Apr 30, 2026 says.
Directors and officers
29
report now, of 59 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Vanguard Capital Management
SCHEDULE 13G · filed Apr 30, 2026 · Common Stock
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 10% in Mar 6, 2025
What MRK reports owning in othersstakes of 5% or more, and other ties
Evaxion A/S EVAX
SCHEDULE 13G/A · filed Feb 3, 2025 · American Depositary Shares, each representing fifty Ordinary Shares, DKK 0.25 nominal value per share
Personalis, Inc. PSNL
SCHEDULE 13G · filed Dec 23, 2024 · Common Stock, $0.0001 par value per share
Other ties the annual report names
Elanco Animal Health Incorporated Aqua Business
A company bought · acquisition · Jun 2024 · owns, named in the 10-K filed Feb 24, 2026
Cidara Therapeutics, Inc.
A company bought · asset acquisition · owns, named in the 10-K filed Feb 24, 2026
Eyebiotech Limited
A company bought · asset acquisition · owns, named in the 10-K filed Feb 24, 2026
Harpoon Therapeutics, Inc.
A company bought · asset acquisition · owns, named in the 10-K filed Feb 24, 2026
HRS-5346, Jiangsu Hengrui Pharmaceuticals Co., Ltd.
A company bought · asset acquisition · owns, named in the 10-K filed Feb 24, 2026
Imago BioSciences, Inc.
A company bought · asset acquisition · owns, named in the 10-K filed Feb 24, 2026
MK-1045/CN201, Curon Biopharmaceutical
A company bought · asset acquisition · owns, named in the 10-K filed Feb 24, 2026
MK-2010 (LM-299), LaNova Medicines Ltd
A company bought · asset acquisition · owns, named in the 10-K filed Feb 24, 2026
354 subsidiaries in 75 countries, from the list filed with the 10-K filed Feb 24, 2026. Its Form 13F-HR for Jun 30, 2026 lists 13 holdings. The record carries no value for them.
Insider tradesForm 4
34sales
0purchases
0sales on a scheduled plan
11people selling
$71.3Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 3, 2025 to Nov 3, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 3, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window11 of 59 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Zachary Jennifer | EVP, General Counsel | 4 | $25.2M | 0 | 0 | $0 |
| Deluca Richard R. | EVP&Pres, Merck Animal Heallth | 9 | $11.3M | 0 | 0 | $0 |
| Guindo Chirfi | EVP, Access, Policy & Comms | 5 | $8.2M | 0 | 0 | $0 |
| Williams David Michael | EVP,Chief Info&Digital Officer | 5 | $8.1M | 0 | 0 | $0 |
| Davis Robert M | Chairman, CEO & President | 2 | $5.6M | 0 | 0 | $0 |
| Litchfield Caroline | EVP & CFO | 1 | $5.0M | 0 | 0 | $0 |
| Li Dean Y | Executive VP & President, MRL | 2 | $3.0M | 0 | 0 | $0 |
| Maraldo David R. | EVP & Pres. MMD | 3 | $2.4M | 0 | 0 | $0 |
| Oosthuizen Johannes Jacobus | EVP, Oncology & Int?l | 1 | $1.8M | 0 | 0 | $0 |
| Smart Dalton | SVP Fin. - Global Controller | 2 | $800,000 | 0 | 0 | $0 |
| Downing Cristal N | Chief Comm. & Public Afrs Ofcr | 1 | $600,000 | 0 | 0 | $0 |